#1 out of 3300.00%
health1d ago
Patients, doctors hail ‘revolutionary’ new drug for pancreatic cancer
Wbez.org and 6 more
- In metastatic pancreatic cancer, daraxonrasib doubles median survival versus standard chemotherapy, highlighting its potential as a next-generation KRAS therapy.
- A 500-patient trial shows daily daraxonrasib nearly doubles survival time with fewer severe side effects than chemotherapy.
- Revolution Medicines’ KRAS approach uses a molecular glue to bind with multiple KRAS subtypes, expanding targets beyond a single mutation.
Vote 20







